Genome-wide association studies indicate that SLC2A2 sequence variation associates with risk of fasting hyperglycaemia, progression to type 2 diabetes, hypercholesterolaemia and cardiovascular diseases. This evidence concerns the gene SLC2A2 and type 2 diabetes mellitus.